Trials / Withdrawn

WithdrawnNCT05178654

Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.

A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO INVESTIGATE THE MASS BALANCE, METABOLISM AND EXCRETION OF [14C]PF-07321332 IN HEALTHY MALE PARTICIPANTS

Status: Withdrawn
Phase: Phase 1
Study type: Interventional
Enrollment: 0 (actual)

Sponsor: Pfizer · Industry
Sex: Male
Age: 18 Years
Healthy volunteers: Accepted

Summary

This study is to characterize mass balance and further the understanding of human pharmacokinetics, metabolism, and excretion of radiolabeled \[14C\]PF-07321332 in healthy male participants following oral administration with ritonavir.

Conditions

Healthy Participants

Interventions

Type	Name	Description
DRUG	[14C]PF-07321332	Single oral dose of 300 mg \[14C\]PF-07321332 containing approximately 100 µCi \[14C\]PF-07321332 coadministered with 100 mg ritonavir.

Timeline

Start date: 2022-02-22
Primary completion: 2022-04-01
Completion: 2022-04-01
First posted: 2022-01-05
Last updated: 2022-01-31

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT05178654. Inclusion in this directory is not an endorsement.